Alcon Inc., the eye-care company set to be spun off from drugmaker Novartis AG next week, is looking to move more swiftly in bringing products to the market and doing deals worth as much as $300 million apiece.
The pace of the pharmaceutical industry “is different from the speed at which Alcon can operate on its own, and which we really need to operate to be competitive,” Alcon Chief Executive Officer David Endicott said in an interview April 4. “We think we can do certain things a good bit faster.”
David Endicott
Source: Novartis AG
The split has been billed as a way to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.